Skip to main content
. 2018 Feb 1;8:2072. doi: 10.1038/s41598-018-20370-9

Figure 3.

Figure 3

JP4-039 mitigates TBI-induced barrier dysfunction. JP4-039 (JP4, 20 mg/kg in F14 emulsion) or vehicle (Ctrl) was given to mice once 24 hr after 9.25 Gy TBI. Intestinal tissues were analyzed at indicated times (day) after TBI. (A) Mucosal expression of ZO-1, ZO-2 and Occludin mRNAs. cDNA was synthesized from RNA pooled from 3 mice per group. Expression was normalized to that on Day 0, prior to TBI. (B) Representative immunohistochemistry staining of Ly-6B.2 (neutrophils) in the villi. Scale bar = 25 µm. (C) Quantification of neutrophils in the crypts and (D) villi. (A,C,D) values are Mean ± SEM; n = 3 mice in each group. ***P < 0.001, *P < 0.05, vehicle vs. JP4, unpaired 2-tailed Student’s t test. +++P < 0.001, ++P < 0.01, 1-way ANOVA followed by Tukey’s multiple comparisons test.